Marvel Biosciences Expands Private Placement to Quebec
Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Compa
2026-08-19 1:06 PM EDT | Marvel Biosciences Corp.
Illumisoft Appoints Ehsan Agahi as CEO, Commences Trading on OTCQB Venture Market, Announces Shares for Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") today announced that Ehsan Agahi, currently Executive Chairman of the Company, has been appointed Chief Executive Officer, effective August 19, 2026. Mr. Agahi will continue to serve as Chairman of the Board. As Executive Chairman since the completion of the Company's qualifying transaction, Mr. Agahi has been closely involved in Illumiso
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-08-19 7:18 AM EDT | Illumisoft Lighting Corp.
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regul
Biotechnologies, Pharmaceutique
2026-08-19 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same." The Notice of Allowance confirms that all
2026-08-18 5:05 PM EDT | Noveris Health Sciences Inc.
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or
Biotechnologies, Pharmaceutique
2026-08-18 8:00 AM EDT | PharmaTher Holdings Ltd.
PharmaCorp Closes Previously Announced Western Canada Pharmacy Acquisition and Announces Two Additional Definitive Agreements
Purchase price of approximately $2.47 million Acquisition increases PharmaCorp's operating network to 16 pharmacies New definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 million New definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western Canada Saskatoon, Saskatchew
Biotechnologies, Pharmaceutique, Commerce de détail
2026-08-18 8:00 AM EDT | PharmaCorp RX Inc.
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program
2026-08-17 7:40 AM EDT | OS Therapies
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnologies, Pharmaceutique, Santé
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Strategic Investment in Production Expansion: Impact Fusion International (IFUS) Installs Proprietary Machinery to Enhance Production Capacity
Napoleonville, Louisiana--(Newsfile Corp. - August 17, 2026) - IFUS (OTCID: IFUS) has installed a retrofitted Selco/Mosley Badger Double Ram Press. Per the Equipment Commissioning Plan, both SGP+™ and SAG™ will now be produced for validation to ensure consistent and sustainable product quality. Delivery and installation, supported by the Harris Bailer Distributor Crigler, has ensured that retrofitted production capability is consistent with IFUS' Proprietary Formulation and
2026-08-17 12:01 AM EDT | Impact Fusion International Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated. "While ATI-1801 remains the Company's principal
Biotechnologies, Pharmaceutique, industries.supplementary-medicine.name
2026-08-14 5:00 PM EDT | Appili Therapeutics Inc.
Secretary of State Randeep Sarai Visits University of Calgary to Learn About Biosenta's Tri-Filler(TM) Technology
Ontario and Calgary, Alberta--(Newsfile Corp. - August 14, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta") was honoured to welcome the Honourable Randeep Sarai, Secretary of State (International Development), to the University of Calgary for a visit highlighting Canadian innovation and the ongoing research behind Biosenta's proprietary Tri-FillerTM technology.
Biotechnologies, Produits chimiques, Produits ménagers / de consommation / cosmétiques
2026-08-14 9:06 AM EDT | Biosenta Inc.
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival benefit observed between 2-year and 2.5-year timepoints U.K. MHRA Statistical Methods Scientific Advice Meeting gra
2026-08-13 8:45 AM EDT | OS Therapies
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnologies, Pharmaceutique, Santé
2026-08-12 8:23 AM EDT | Hemostemix Inc.
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D P
Biotechnologies, Pharmaceutique
2026-08-11 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnologies, Pharmaceutique, Santé
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue gener
Technologies, Biotechnologies, Santé
2026-08-11 6:00 AM EDT | Restart Life Sciences Corp.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnologies, Pharmaceutique, Santé
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.